Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ruxolitinib phosphate
Find trials that include:  Any drugs shown
Results 1-25 of 32 for your search:
Start Over
Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 1 to 18
Trial IDs: TOT17, NCI-2017-00582, NCT03117751
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Ruxolitinib Phosphate and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM1906, NCI-2014-02015, NCT02066532
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Ruxolitinib Phosphate and Decitabine in Treating Patients with Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0344, NCI-2014-02299, NCT02257138
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY007, NCI-2016-00203, NCT02713386
Ruxolitinib Phosphate and Panobinostat in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-1225, NCI-2017-00654, NCT01693601
Ruxolitinib Phosphate in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma after Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 283-11, NCI-2011-02733, 12C0196, NCT01431209
Ruxolitinib Phosphate in Treating Patients with Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-024, NCI-2012-00992, NCT01562873
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-258, NCI-2011-03132, NCT01348490
Ruxolitinib Phosphate in Treating Patients With Adult T-Cell Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0006, NCI-2013-01560, 130006, 335354, P12996, NCT01712659
Ruxolitinib Phosphate and Exemestane in Treating Patients With Estrogen Receptor-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 02112, NCI-2012-00745, NCT01594216
Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0737, NCI-2013-00704, NCT01787487
Ruxolitinib Phosphate Before Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: MPD-RC 114, NCI-2014-01258, 12-00826, 12-1809, GCO 12-1809, NCT01790295
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00010262, NCI-2014-00633, 10262, NCT02092324
Ruxolitinib Phosphate in Reducing Fatigue in Patients with Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2013-0044, NCI-2014-01465, NCT02131584
JAK Inhibitor before Donor Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9033, NCI-2014-01882, NCT02251821
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 1 to 21
Trial IDs: INCB 18424-269, NCI-2016-01687, AALL1521, NCT02723994
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: INCB 18424-271 (REACH1), NCI-2016-01824, INCB 18424-271, INCB 18424-271/REVERSE-1, NCT02953678
Ruxolitinib in Treating Patients with Relapsed or Refractory T-cell or NK Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-1542, NCI-2016-01850, NCT02974647
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-270, NCI-2017-00377, NCT02955940
Ruxolitinib and Thalidomide in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Myelofibrosis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-1498, NCI-2017-00448, NCT03069326
Ruxolitinib Phosphate in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0570, NCI-2017-00478, NCT03041636
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-272 (RESET-272), NCI-2017-00828, INCB 18424-272, NCT03123588
Start Over